Publication | Closed Access

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials

Diabetes ManagementUrologyRenal FunctionMedicineDiabetesType 2Once-weekly Subcutaneous SemaglutideDiabetic Kidney DiseaseSustain 1–7Diabetes MellitusChronic Kidney DiseaseNephrology